期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

赫赛汀与化疗药物联合应用治疗转移性乳腺癌进展 被引量：1

Progress of Herceptin and chemotherapeutic drugs combination in treatment of metastatic breast cancer
暂未订购
导出
摘要 赫赛汀单独应用治疗HER 2过度表达的转移性乳腺癌可作为一个二线或三线药物 ,2 2 2例患者总的缓解率为15 % ,中位缓解期 9.1个月 ,明显优于原来化疗的 5 .2个月。赫赛汀与不同的化疗药物联用治疗HER 2过度表达的转移性乳腺癌具有协同或增强作用。
作者 徐峰 胡莲 廖志勇
机构地区 第一军医大学珠江医院 Lab of Molecular Pharmacology
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2003年第2期140-142,共3页 Chinese Journal of Cancer Biotherapy
关键词 赫赛汀 化疗药物 联合应用 治疗 转移性乳腺癌
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1Vogel C, Cobleigh M, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 over-expressing metastatic breast cancer [ J]. J Clin Oncol, 2002, 20:719-726.
  • 2Workman P. New drug targets for genomic cancer therapy: Successes, limitations, opportunities and future challenges[J]. Curr Cancer Drug Targets, 2001, 1 : 33-47.
  • 3Baselga J, Albanell J. Mechanism of action of anti-HER-2 monoclonal antibodies[J]. Ann Oncol, 2001, 12(suppl 1) : S35-41.
  • 4Mayfield S, Vaughn JP, Kute TE. DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines [J ].Breast Cancer Res Treat, 2001,70 : 123-129.
  • 5Leyland-Jones B. Dose scheduling-Herceptin [ J ]. Oncology,2001,61 (suppl 2): 31-36.
  • 6Baselga J. Phase Ⅰ and and Ⅱ clinical trials of transtuzumab [ J].Ann Oncol, 2001, 12(suppl 1 ) : S49-55.
  • 7Cobleigh M, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease[J]. J Clin Oncol. 1999. 17(9): 2639-2648.
  • 8Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER-2 antibody ( Herceptin ) enhances the antitumor activity of paclitaxel and doxorubicin against HER-2/neu overexpressing human breast cancer xenografts [ J]. Cancer Res, 1998, 58 ( 13 ) :2825-2831.
  • 9Norton L, Slamon D, Leyland-Jones B, et al. Overall survival(OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER-2 monoclonal antibody Herceptin (H) in HER-2-overexpressing ( HER-2 + ) metastatic breast cancer ( MBC )[J]. Proc Am Soc Clin Oncol, 1999, 18: 127a.
  • 10Pietras R, Pegram M, Finn R, et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HEB-2 receptor and DNA-reactive drugs [J]. Oncogene, 1998,17 : 2235-2249.

同被引文献6

引证文献1

二级引证文献9

中国肿瘤生物治疗杂志
2003年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部